77.5 B+
Retatrutide
Also known as: LY3437943
Strong Clinical Evidence Research Chemical
Research Evidence 90.0/100
Safety Profile 65.0/100
33 Clinical Trials
PHASE3: 13 PHASE2: 4 PHASE1: 15 NA: 1
- A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight PHASE3 RECRUITING Eli Lilly and Company
- A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight PHASE3 RECRUITING Eli Lilly and Company
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain PHASE3 RECRUITING Eli Lilly and Company
- A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity PHASE3 ACTIVE_NOT_RECRUITING Eli Lilly and Company
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity PHASE3 ACTIVE_NOT_RECRUITING Eli Lilly and Company
Showing 5 of 33 trials.
15 Research Papers
- The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities. Clin Pharmacol Drug Dev Review
- Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison. Int J Obes (Lond) unknown
- Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis. Cardiol Rev unknown
- Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders. Eur J Med Chem Review
- [Nephrology : what's new in 2025]. Rev Med Suisse unknown
Showing 5 of 15 papers by citation count.
FDA Data
Not FDA-Approved
Retatrutide has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
Frequently Asked Questions
Is Retatrutide FDA approved?
No, Retatrutide has not been approved by the FDA for human therapeutic use. It is sold as a research chemical.
How many clinical trials has Retatrutide been studied in?
Retatrutide has been studied in 33 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for Retatrutide?
Retatrutide has a CheckPeptides trust score of 77.5/100 (grade: B+). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026
Quick Facts
- Classification
- GLP-1/GIP/Glucagon triple agonist
- Molecular Weight
- 4731.0 Da
- PubChem
- CID 171390338 ↗
- Regulatory Status
- N/A
Score Breakdown
Research Evidence 90.0/100
Safety Profile 65.0/100
Evidence Summary
- Clinical Trials
- 33
- Research Papers
- 15
- Trust Score
- 77.5/100
- Grade
- B+